Sun Pharma eyeing high single-digit top-line growth in current financial year

31 May 2022 Evaluate

Sun Pharmaceutical Industries is eyeing high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1786.05 -40.05 (-2.19%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.